Lipid accumulation product index: A reliable marker of cardiovascular risk in polycystic ovary syndrome

Human Reproduction

Volumn 24, Issue 7, 2009, Pages 1726-1731

  Wiltgen, D ^a,b,c   Benedetto, I G ^a,b   Mastella, L S ^a,b   Spritzer, P M ^a,b,c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c National Institute of Hormones and Women's Health CNPq   (Brazil)

Author keywords

Cardiovascular disease; Homeostasis model assessment index; Insulin resistance; Lipid accumulation product index; Polycystic ovary syndrome

Indexed keywords

CHOLESTEROL; GLUCOSE; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; LIPID;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; LIPID ACCUMULATION PRODUCT INDEX; LIPID STORAGE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; CHEMISTRY; GLUCOSE TOLERANCE TEST; METABOLISM; REPRODUCIBILITY; RISK;

ADOLESCENT; ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; LIPIDS; POLYCYSTIC OVARY SYNDROME; REPRODUCIBILITY OF RESULTS; RISK; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 69149100493     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dep072     Document Type: Article

References (29)

1. Alhassan S, Kiazand A, Balise RR, King AC, Reaven GM, Gardner CD. Metabolic syndrome: do clinical criteria identify similar individuals among overweight premenopausal women. Metabolism 2008;57:49-56.
2. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-1935.
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-4245.
4. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
5. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population. Diabetes Care 2007;30:318-324.
6. Chevenne D, Trivin F, Porquet D. Insulin assays and reference values. Diabetes Metab 1999;25:459-476.
7. Cussons JA, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BGA. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008;23:2352-2352
8. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-E223.
9. Donato GB, Fuchs SC, Oppermann K, Bastos C, Spritzer PM. Menopausal status is associated with central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause 2006; 13:280-285.
10. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65:499-507.
11. Ehrmann DA. Obesity and glucose intolerance in androgen excess. In: Azziz R, Nestler JE, Dewailly D (ed). Androgen Excess Disorders in Women. Philadelphia: Lippincott-Raven, 1997, 705-712.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285:2486-2497.
13. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
14. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52:908-915.
15. Kahn HS. The 'lipid accumulation product' performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005;5:26.
16. Kahn AS, Valdez R. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr 2003;78:928-934.
17. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993;137:959-965.
18. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
19. Lemiex I, Pascot A, Couillard C, Lamarche D, Tchernof A, Alméras N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D et al. Hypertricyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-184.
20. Olefsky JM, Farquhar JW, Reaven G. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetics subjects. Diabetes 1973;22:507-513.
21. Spritzer P, Billaud L, Thalabard JC, Birman P, Mowszowicz I, Raux-Demay MC, Clair F, Kuttenn F, Mauvais-Jarvis P. Cyproterone acetate versus hydrocortisone treatment in late onset adrenal hyperplasia. J Clinl Endocrino Metab 1990;70:642-645.
22. Spritzer PM, Wiltgen D. Prevalence of metabolic syndrome in patients of south Brazil with polycystic ovary syndrome (PCOS). Arq Bras Endocrinol Metab 2007;51:146-147.
23. Tankó BL, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 2005;111: 1883-1890.
24. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2003; 81:19-25.
25. Toscani M, Migliavacca R, Sisson de Castro JA, Spritzer PM. Estimation of truncal adiposity using waist circumference or the sum of trunk skinfolds: a pilot study for insulin resistance screening in hirsute patients with or without polycystic ovary syndrome. Metabolism 2007; 56:992-997.
26. Wallace TR, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
27. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 2000;52:595-600. (Pubitemid 30337085)
28. World Health Organization. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995;854:1-452.
29. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Report of WHO Consultation: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO, 1999.